132
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Using first-contact serum ferritin to predict severe thrombocytopenia in dengue patients: determination and validation in independent cohorts

, ORCID Icon, &
Pages 425-430 | Received 10 Sep 2021, Accepted 18 Jan 2022, Published online: 26 Jan 2022
 

Abstract

Background

Severe thrombocytopenia and associated haemorrhage are dreaded complications of dengue fever. The identification of a biomarker that can predict, or rule out, its subsequent development can help identify at-risk individuals.

Methods

200 dengue patients were included – the first 100 in the deterministic cohort and the latter, the validation cohort. Serum ferritin levels were measured at first presentation. Platelets were monitored serially. Data from the first cohort was used to determine the optimal ferritin level to predict significant thrombocytopenia (<20,000/µL). This threshold was validated in the second cohort.

Results

In the deterministic cohort, a ferritin threshold of 593 ng/mL predicted severe thrombocytopenia with a sensitivity of 93.33%, negative predictive value of 98.18% and negative likelihood ratio (LR-) of 0.10. In the validation cohort, the sensitivity and negative predictive value of this threshold were both 100%. The power of the study (determined post-hoc) for each cohort was 98.4% and 86.4% respectively.

Conclusion

First-contact ferritin consistently identified at-risk individuals. Individuals with ferritin levels below 593 ng/mL were unlikely to develop severe thrombocytopenia independent of clinical presentation.

Acknowledgements

The authors would like to thank Dr. Ajay Pillai, Dr. Ruby Taparia, and Dr. Romil Parikh for their expertise and critical insights.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Authorship statement

All listed authors fulfilled the ICMJE requirements for authorship.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.